Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $29.0909.

ELAN has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. UBS Group increased their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th.

Elanco Animal Health Stock Up 5.0%

ELAN opened at $23.64 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health has a fifty-two week low of $17.11 and a fifty-two week high of $27.98. The firm’s fifty day moving average is $24.56 and its 200 day moving average is $24.02. The stock has a market cap of $11.81 billion, a price-to-earnings ratio of -57.65, a price-to-earnings-growth ratio of 1.35 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the firm posted $0.26 EPS. Elanco Animal Health’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts forecast that Elanco Animal Health will post 1.12 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Paul Herendeen acquired 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the transaction, the director directly owned 111,687 shares in the company, valued at approximately $2,644,748.16. This represents a 9.83% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael J. Harrington bought 5,000 shares of the stock in a transaction dated Wednesday, August 12th. The stock was bought at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the acquisition, the director directly owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 19,200 shares of company stock worth $442,836 over the last quarter. Insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Elanco Animal Health during the second quarter valued at about $1,202,198,000. Primecap Management Co. CA purchased a new stake in shares of Elanco Animal Health in the second quarter worth about $1,118,402,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Elanco Animal Health in the second quarter worth about $205,636,000. UBS Group AG boosted its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after buying an additional 4,975,721 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.